Busulfan Tablets

It is a bifunctional alkylating agent belonging to the class of bismethyl sulfonates and is a non-specific drug for the cell cycle. When it enters the human body, the ring structure of the sulfonate group opens and destroys the structure and function of DNA by alkylating guanine in the cell's DNA. The cytotoxic effect of this product is almost entirely manifested in the inhibition of hematopoietic function, mainly manifested in the obvious inhibition of granulocyte production. The second is the inhibition of platelets and red blood cells, and the inhibition of lymphocytes is very weak.

Its chemical name is: 1,4-Butanediol dimethanesulfonate. Its structural formula is: Molecular formula: C6H14O6S2 Molecular weight: 246.29.

This product is a sugar-coated tablet, which appears white after removing the sugar coating.

It is mainly used in the chronic phase of chronic myeloid leukemia, and has poor effects on patients lacking the Philadelphia chromosome Ph1. It can also be used to treat chronic myeloproliferative diseases such as essential thrombocythemia and polycythemia vera.

Common dosage for adults: For chronic myeloid leukemia, the total daily amount is 4-6 mg/m2, once a day. If the white blood cell count drops to 20×109/L, the drug should be discontinued as appropriate. Or a maintenance dose of 1-2 mg per day or every other day is given to maintain the white blood cell count at around 10×109/L.

Bone marrow suppression may occur. Common symptoms include granulocytopenia and thrombocytopenia. In severe cases, the drug should be discontinued immediately. Long-term use or excessive use may cause pulmonary fibrosis. Skin pigmentation, hyperuricemia and sexual dysfunction, feminization of male breasts, testicular atrophy, and irregular menstruation in women may occur. Cataracts, erythema multiforme rash, and polyarteritis nodosa are rare adverse reactions. There have been individual reports of epileptic seizures after high doses; endocardial fibrosis, and the corresponding symptoms; and rare hepatic venous atresia.

This product may increase the risk of fetal death and congenital malformations, so it should not be used in the first three months of pregnancy. Patients who have been allergic to this drug in the past.

Because taking this product can increase the level of uric acid in the blood and urine, anti-gout drugs can be used for patients with a history of gout or patients with increased uric acid after taking this product.

Sealed, store in a dry place.

0.5mg